Cargando…

Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab

BACKGROUND: Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life‐threatening autoimmune thrombotic microangiopathy. Current standard of care is therapeutic plasma exchange, immunosuppression, and caplacizumab, an anti‐von Willebrand factor nanobody, which is effective in treating aTTP...

Descripción completa

Detalles Bibliográficos
Autores principales:	Völker, Linus A., Brinkkoetter, Paul T., Knöbl, Paul N., Krstic, Miroslav, Kaufeld, Jessica, Menne, Jan, Buxhofer‐Ausch, Veronika, Miesbach, Wolfgang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	PLATELETS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692904/ https://www.ncbi.nlm.nih.gov/pubmed/32757435 http://dx.doi.org/10.1111/jth.15045

Ejemplares similares

Caplacizumab for thrombotic thrombocytopenic purpura
Publicado: (2020)

Caplacizumab for Acute Thrombotic Thrombocytopenic Purpura
por: Katsivalis, Katherine V., et al.
Publicado: (2021)

Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura
por: Hanlon, Ashley, et al.
Publicado: (2020)

Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry
por: Agosti, Pasquale, et al.
Publicado: (2023)

Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura
por: Elverdi, Tugrul, et al.
Publicado: (2019)

Caplacizumab: frequent local skin reactions
por: Kaufeld, Jessica, et al.
Publicado: (2020)

Thrombotic thrombocytopenic purpura
por: Knöbl, Paul
Publicado: (2018)

Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab
por: Sukumar, Senthil, et al.
Publicado: (2020)

Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura
por: Westwood, John-Paul, et al.
Publicado: (2014)

Clinical Efficacy and Safety Profile of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
por: Maqsood, Muhammad Haisum, et al.
Publicado: (2019)

Diagnostic uncertainty presented barriers to the timely management of acute thrombotic thrombocytopenic purpura in the United Kingdom between 2014 and 2019
Publicado: (2022)

More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura
por: Picod, Adrien, et al.
Publicado: (2022)

Delayed Thrombotic Complications in a Thrombotic Thrombocytopenic Purpura Patient Treated With Caplacizumab
por: Cilla, Nicolas, et al.
Publicado: (2020)

How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura?
por: Zheng, Lucy, et al.
Publicado: (2023)

Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data
por: Gavriilaki, Eleni, et al.
Publicado: (2023)

Post Approval Experience with Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura at a Single Institution
por: Logothetis, Constantine N., et al.
Publicado: (2021)

Caplacizumab Model‐Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura
por: Bergstrand, Martin, et al.
Publicado: (2021)

Brazilian experience with caplacizumab in acquired thrombotic thrombocytopenic purpura: outcomes of the expanded access program
por: de Oliveira Boechat, Tiago, et al.
Publicado: (2023)

Blood–brain barrier permeability in survivors of immune-mediated thrombotic thrombocytopenic purpura: a pilot study
por: Huang, Shih-Han Susan, et al.
Publicado: (2021)

Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study
por: Knoebl, Paul, et al.
Publicado: (2019)

Outcomes in 1096 patients with severe thrombotic thrombocytopenic purpura before the Caplacizumab era
por: Van de Louw, Andry, et al.
Publicado: (2021)

Prolonged Exposure to Caplacizumab as Rescue Therapy in Refractory Immune Thrombotic Thrombocytopenic Purpura
por: Rodgers, George M, et al.
Publicado: (2023)

Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura
por: Bruzzese, Antonella, et al.
Publicado: (2023)

Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura
por: Izquierdo, Cristina Pascual, et al.
Publicado: (2022)

Successful Treatment of Refractory Thrombotic Thrombocytopenic Purpura (TTP) With Caplacizumab: A Case Report
por: Pramanik, Debolina, et al.
Publicado: (2023)

Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis
por: Djulbegovic, Mia, et al.
Publicado: (2022)

Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study
por: Miesbach, Wolfgang, et al.
Publicado: (2019)

Refractory Auto-Immune Thrombotic Thrombocytopenic Pupura Successfully Treated With Caplacizumab
por: Mellaza, Chloé, et al.
Publicado: (2020)

P1608: REAL-WORLD INSIGHTS ON THE MANAGEMENT OF IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP) WITH CAPLACIZUMAB IN BELGIUM
por: Dierickx, Daan, et al.
Publicado: (2023)

Relapsed Refractory Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Following COVID-19 Vaccination
por: Francisco, Michael T., et al.
Publicado: (2021)

Immune‐mediated thrombotic thrombocytopenic purpura in a Jehovah’s Witness – Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab, steroids and rituximab
por: Cardesa‐Salzmann, Teresa Marta, et al.
Publicado: (2022)

Refractory Thrombotic Thrombocytopenic Purpura to Therapeutic Plasma Exchange
por: Kiamos, Amy, et al.
Publicado: (2022)

Immune-mediated thrombotic thrombocytopenic purpura plasma induces calcium- and IgG-dependent endothelial activation: correlations with disease severity
por: Tellier, Edwige, et al.
Publicado: (2022)

Unmet needs in the management of immune‐mediated thrombotic thrombocytopenic purpura and the potential role of caplacizumab in the UK—A modified‐Delphi study
por: Scully, Marie, et al.
Publicado: (2022)

The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study
por: Miyakawa, Yoshitaka, et al.
Publicado: (2022)

Successful treatment of vaccine‐induced prothrombotic immune thrombocytopenia (VIPIT)
por: Thaler, Johannes, et al.
Publicado: (2021)

The Efficacy and Safety of Plasma Exchange in the Treatment of Thrombotic Thrombocytopenic Purpura
por: Pan, Zhilan, et al.
Publicado: (2022)

P1609: CAPLACIZUMAB THERAPY IN OLDER PATIENTS (≥60 YEARS) WITH IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP). RESULTS OF THE SPANISH TTP REGISTRY
por: Rubia, Javier DE LA, et al.
Publicado: (2023)

The role of ADAMTS‐13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies
por: Phillips, E. H., et al.
Publicado: (2016)

Thrombotic Thrombocytopenic Purpura and Gemcitabine
por: Kasi, Pashtoon Murtaza
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_lpq08f4c2hb5c5k8gtsevqq0if